SCHEMBL681118

SCHEMBL681118

CNC(=O)CC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19176775 0.83 HPGD (0.42)
SCHEMBL21514115 0.82 HPGD (0.39)
SCHEMBL16092680 0.80 HMGCR (0.50)
SCHEMBL18799386 0.80
SCHEMBL4282052 0.80
SCHEMBL20224633 0.79 MCL1 (0.34)
SCHEMBL21094212 0.79 MCL1 (0.34)
SCHEMBL23890514 0.79 LMNA (0.40)
SCHEMBL1515251 0.79
SCHEMBL2409147 0.79 CYP1A2 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 US claimed
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2018-12-13 US claimed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 EP claimed
CN-102596913-B Cannabinoid receptor modulators 艾尼纳制药公司 2016-11-09 CN claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 US claimed
CN-102596913-A Cannabinoid receptor modulators ARENA PHARM INC 2012-07-18 CN claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 WO claimed
US-20100163070-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE L'OREAL S.A. (FR) 2010-07-01 US claimed
EP-1250332-A1 INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION Abbott Laboratories (US) 2002-10-23 EP claimed
WO-2001044223-A1 INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION ABBOTT LABORATORIES (US) 2001-06-21 WO claimed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-12024500-B2 Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) 2024-07-02 US disclosed
EP-4329810-A1 TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS Perfuse Therapeutics, Inc. (US) 2024-03-06 EP disclosed
EP-0546409-B1 Method for the preparation of tetrahydropyrancarboxylic esters BASF AG (DE) 1998-10-21 EP disclosed
EP-0721454-A1 NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST J. URIACH &amp; CIA. S.A. (ES) 1996-07-17 EP disclosed
WO-1996004273-A1 NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST J. URIACH & CIA, S.A. (ES) 1996-02-15 WO disclosed
EP-0546409-A1 Method for the preparation of tetrahydropyrancarboxylic esters BASF Aktiengesellschaft (DE) 1993-06-16 EP disclosed